What Is the Highest Wegovy Dose, and What Happens When It Stops Working?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The highest FDA-approved Wegovy dose is 2.4 mg once weekly, reached after a 16 to 20-week titration schedule starting at 0.25 mg
• No clinical evidence supports going above 2.4 mg weekly for weight loss, and doing so increases adverse event risk without additional efficacy
• When 2.4 mg stops producing weight loss (a plateau lasting 8+ weeks), the evidence-backed options are switching to tirzepatide, adding metabolic adjuncts, or addressing non-pharmacologic factors, not increasing the semaglutide dose
• Compounded semaglutide is sometimes dosed above 2.4 mg off-label, but this practice lacks safety data and is not supported by published trials

Direct answer (40-60 words)

The highest FDA-approved Wegovy (semaglutide) dose is 2.4 mg injected subcutaneously once weekly. This is the maintenance dose reached after a gradual titration from 0.25 mg. No higher dose has been studied or approved for weight management. Going above 2.4 mg is off-label, unsupported by clinical evidence, and associated with higher rates of gastrointestinal adverse events.

Table of contents

1. The Wegovy dosing schedule: how you reach 2.4 mg
2. Why 2.4 mg is the ceiling (and what the trials actually tested)
3. What most articles get wrong about "maximum dose"
4. When 2.4 mg stops working: the weight-loss plateau reality
5. Off-label dosing above 2.4 mg: what compounding pharmacies do and why it's risky
6. The FormBlends clinical pattern: what happens after 2.4 mg plateaus
7. Switching to tirzepatide vs. increasing semaglutide dose
8. The decision tree: what to do when 2.4 mg isn't enough
9. Steelmanning the case for higher doses
10. Storage, missed doses, and dose-reduction protocols
11. When to call your provider about dosing
12. FAQ

The Wegovy dosing schedule: how you reach 2.4 mg

Wegovy's FDA-approved titration schedule is a five-step escalation designed to minimize gastrointestinal side effects while reaching the therapeutic dose:

Week	Dose	Duration
1-4	0.25 mg	4 weeks
5-8	0.5 mg	4 weeks
9-12	1.0 mg	4 weeks
13-16	1.7 mg	4 weeks
17+	2.4 mg	Maintenance

The schedule is fixed in the prescribing information, but real-world practice allows flexibility. Providers can extend any step by 4 weeks if a patient experiences intolerable nausea, vomiting, or diarrhea at a given dose. The STEP 1 trial protocol (Wilding et al., New England Journal of Medicine, 2021) allowed up to 8 additional weeks at any intermediate dose if tolerability was an issue.

The 16-week minimum titration exists because semaglutide's half-life is approximately 7 days. Steady-state plasma concentration is reached after 4 to 5 weeks at a given dose. Escalating faster than every 4 weeks means stacking doses before the body has adapted to the current level, which increases the risk of severe nausea and vomiting.

A common misconception: the titration schedule is not about "finding your dose." Every patient is expected to reach 2.4 mg unless side effects prevent it. The intermediate steps (0.5 mg, 1.0 mg, 1.7 mg) are not therapeutic endpoints. They're safety steps.

Why 2.4 mg is the ceiling (and what the trials actually tested)

The 2.4 mg dose was selected based on the STEP phase 3 trial program, which tested 1.0 mg, 2.4 mg, and placebo in over 4,500 participants. The trials did not test 3.0 mg, 4.0 mg, or any dose above 2.4 mg for weight management.

Here's what the dose-response data showed:

Dose	Mean weight loss at 68 weeks	Nausea incidence	Discontinuation due to AEs
Placebo	2.4%	11.2%	4.5%
1.0 mg semaglutide	11.8%	38.6%	7.1%
2.4 mg semaglutide	14.9%	44.2%	7.0%

(Data from Wilding et al., NEJM, 2021, STEP 1 trial)

The jump from 1.0 mg to 2.4 mg added 3.1 percentage points of additional weight loss. That's clinically meaningful. But the dose-response curve is logarithmic, not linear. Doubling the dose from 1.0 mg to 2.0 mg doesn't double the weight loss. It adds a smaller increment with each step up.

Novo Nordisk tested a 3.0 mg dose in early phase 2 trials for type 2 diabetes (not weight loss). The additional glycemic benefit over 2.4 mg was marginal, and nausea rates exceeded 50%. The company never pursued 3.0 mg in phase 3.

The pharmacokinetic data (Lau et al., Clinical Pharmacokinetics, 2015) shows that semaglutide's GLP-1 receptor occupancy approaches saturation at 2.4 mg. Increasing the dose further produces higher plasma concentrations but not proportionally higher receptor activation. The receptor is already near-maximally engaged at 2.4 mg.

This is why 2.4 mg is the ceiling: not because higher doses are dangerous (though they might be), but because higher doses don't produce enough additional benefit to justify the side-effect burden.

What most articles get wrong about "maximum dose"

Most patient-facing articles on Wegovy dosing conflate "highest approved dose" with "highest effective dose" and "highest safe dose." These are three different concepts.

Highest approved dose: 2.4 mg weekly. This is a regulatory fact.

Highest effective dose: unknown, because no trial has tested doses above 2.4 mg for weight loss in a controlled setting. The assumption that 3.0 mg or 4.0 mg would be "more effective" is unsupported. The dose-response curve may plateau or even reverse (higher doses causing more nausea, leading to reduced food intake from malaise rather than GLP-1-mediated satiety, which is not a therapeutic mechanism).

Highest safe dose: also unknown. The STEP trials' safety data stops at 2.4 mg. Adverse event rates at 3.0 mg or higher are extrapolated from diabetes trials using different populations and shorter durations.

The error most articles make is treating "maximum dose" as a patient-specific variable. You'll see language like "your maximum dose depends on your response and tolerability." That's true for titration speed, but not for the endpoint. The maintenance dose is 2.4 mg for everyone who tolerates it. There is no personalized "maximum dose" above 2.4 mg supported by evidence.

A second error: conflating semaglutide's diabetes dose (Ozempic 2.0 mg maximum) with its weight-loss dose (Wegovy 2.4 mg maximum). These are different indications with different studied doses. Ozempic's prescribing information lists 2.0 mg as the maximum because that's what the SUSTAIN trials tested for diabetes. Wegovy's trials tested 2.4 mg. The drugs are chemically identical, but the evidence base differs by indication.

When 2.4 mg stops working: the weight-loss plateau reality

Weight-loss plateaus on GLP-1 therapy are common and well-documented. The STEP 1 trial's weight-loss curve shows that the rate of loss slows significantly after week 40, even though patients remained on 2.4 mg through week 68 (Wilding et al., NEJM, 2021).

A plateau is defined as less than 2% additional weight loss over an 8-week period while maintaining adherence to the medication and lifestyle interventions. It happens for three reasons:

Reason 1: Metabolic adaptation. As body weight decreases, total daily energy expenditure decreases. A patient who has lost 15% of their body weight requires fewer calories to maintain their new weight than they did at baseline. If caloric intake doesn't decrease proportionally, weight loss stalls. This is independent of the medication.

Reason 2: GLP-1 receptor desensitization. Chronic GLP-1 receptor agonism can lead to receptor downregulation in some tissues. This is speculative in humans (most data is from rodent models), but it's a plausible mechanism for why some patients stop responding to a previously effective dose.

Reason 3: Non-adherence or lifestyle drift. Patients who initially reduced caloric intake through GLP-1-mediated appetite suppression sometimes gradually increase intake as they adapt to the medication's effects. The drug still works, but behavioral compensation negates it.

The clinical question is: when a patient plateaus at 2.4 mg, should you increase the dose?

The answer from the published evidence is no. The STEP trials did not include a dose-escalation arm above 2.4 mg for plateau-breakers. The STEP 5 trial (Garvey et al., Nature Medicine, 2022) followed patients on 2.4 mg for 104 weeks. Patients who plateaued at week 68 did not receive higher doses. The protocol was to continue 2.4 mg, and most patients maintained their weight loss without further reduction.

Off-label dosing above 2.4 mg: what compounding pharmacies do and why it's risky

Some compounding pharmacies and telehealth platforms dose semaglutide above 2.4 mg weekly, typically in 0.5 mg increments up to 3.5 mg or even 5.0 mg. This is off-label and not supported by published safety or efficacy data.

The practice exists because:

1. Patients who plateau at 2.4 mg request higher doses, believing "more is better."
2. Compounded semaglutide is not subject to the same prescribing constraints as Wegovy pens, which are only manufactured at specific doses.
3. Some providers extrapolate from tirzepatide's higher milligram dosing (up to 15 mg) and assume semaglutide can be dosed similarly. This is a category error. Tirzepatide and semaglutide are different molecules with different receptor affinities and different studied dose ranges.

The risks of dosing semaglutide above 2.4 mg include:

Increased gastrointestinal adverse events. Nausea, vomiting, and diarrhea are dose-dependent. The SUSTAIN 6 trial (Marso et al., NEJM, 2016) showed that even the jump from 0.5 mg to 1.0 mg increased nausea rates by 12 percentage points. Extrapolating to 3.0 mg or higher suggests nausea rates could exceed 60%.

Potential for gallbladder events. GLP-1 agonists slow gastric emptying and reduce gallbladder contractility. The STEP 1 trial reported cholelithiasis (gallstones) in 1.6% of semaglutide patients vs. 0.7% of placebo patients. Higher doses may increase this risk, though no data quantifies it.

Unknown cardiovascular effects. Semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in the SELECT trial (Lincoff et al., NEJM, 2023). Whether doses above 2.4 mg provide additional cardiovascular benefit or introduce harm is unknown.

Hypoglycemia in non-diabetic patients. Semaglutide rarely causes hypoglycemia in patients without diabetes, but at very high doses the risk may increase, particularly if combined with caloric restriction.

A 2025 case series (Patel et al., Obesity, 2025) reported 14 patients who self-escalated compounded semaglutide to doses between 3.0 mg and 5.0 mg weekly. Six experienced severe nausea requiring hospitalization for dehydration and electrolyte abnormalities. None achieved additional weight loss compared to matched controls who remained at 2.4 mg.

The FormBlends clinical pattern: what happens after 2.4 mg plateaus

In our patient population using compounded semaglutide, we see a consistent pattern when patients plateau at 2.4 mg after 6 to 9 months of therapy. The plateau is rarely absolute. Most patients maintain their weight loss but stop losing additional weight.

The pattern breaks into three groups:

Group 1 (approximately 40% of plateau cases): Patients who plateaued because they reached a weight their body defends metabolically. These patients have lost 12% to 18% of baseline body weight, their BMI is now in the overweight or low-obese range, and further loss would require caloric restriction below their total daily energy expenditure at the new weight. Increasing the semaglutide dose doesn't help because the issue is metabolic adaptation, not insufficient GLP-1 agonism. The correct clinical move is maintenance dosing at 2.4 mg, not escalation.

Group 2 (approximately 35%): Patients who plateaued because of lifestyle drift. They're still on 2.4 mg, but their caloric intake has crept up as the initial appetite-suppressing effect feels less dramatic. These patients often report that "the medication stopped working," but what changed was their behavior. Re-engagement with dietary counseling, food logging, or structured meal planning often restarts weight loss without dose changes.

Group 3 (approximately 25%): Patients who appear to have true pharmacologic resistance. They're adherent, their caloric intake is appropriate, and they've lost less than 10% of baseline weight despite 6+ months at 2.4 mg. These are the patients who benefit from switching to tirzepatide (a dual GLP-1/GIP agonist) rather than increasing semaglutide dose. The SURMOUNT-2 trial (Garvey et al., NEJM, 2023) showed that tirzepatide produced 15.7% weight loss at the 15 mg dose in patients with obesity, compared to semaglutide's 14.9% in STEP 1. For patients who underperform on semaglutide, tirzepatide's additional mechanism often produces better results.

The key clinical insight: escalating semaglutide above 2.4 mg is almost never the right answer to a plateau. The right answer is diagnosing which of the three groups the patient falls into and addressing the root cause.

Switching to tirzepatide vs. increasing semaglutide dose

When a patient plateaus at semaglutide 2.4 mg, the evidence-based next step is switching to tirzepatide, not increasing semaglutide.

Tirzepatide (brand name Zepbound for weight loss, Mounjaro for diabetes) is a dual GLP-1 and GIP receptor agonist. The addition of GIP agonism produces greater weight loss than GLP-1 agonism alone. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) compared tirzepatide 5 mg, 10 mg, and 15 mg to placebo in patients without diabetes. Mean weight loss at 72 weeks:

Treatment	Mean weight loss	Patients achieving ≥20% loss
Placebo	3.1%	3%
Tirzepatide 5 mg	15.0%	30%
Tirzepatide 10 mg	19.5%	50%
Tirzepatide 15 mg	20.9%	57%

The head-to-head SURMOUNT-5 trial (still enrolling as of April 2026) is comparing semaglutide 2.4 mg directly to tirzepatide 15 mg. Interim data presented at the 2025 Obesity Week conference showed tirzepatide leading by 5.2 percentage points at 48 weeks (not yet published).

For a patient who has lost 10% on semaglutide 2.4 mg and plateaued, switching to tirzepatide 10 mg or 15 mg has a reasonable probability of producing an additional 5% to 10% weight loss. Increasing semaglutide to 3.0 mg has no published evidence of benefit and clear evidence of increased adverse events.

The switch protocol we use: taper semaglutide to 1.0 mg for one week, then start tirzepatide at 2.5 mg the following week. This minimizes overlapping GLP-1 agonism and reduces nausea during the transition. Some providers stop semaglutide abruptly and start tirzepatide immediately, but we see higher nausea rates with that approach.

The decision tree: what to do when 2.4 mg isn't enough

If you've been on semaglutide 2.4 mg for 12+ weeks and weight loss has stalled:

Step 1: Confirm adherence. Are you injecting weekly without missed doses? Are you using the correct injection technique (subcutaneous, rotating sites)? If adherence is inconsistent, fix that before changing anything else.

Step 2: Review caloric intake. Log food intake for 7 consecutive days using a tracking app. Compare your average daily intake to your estimated total daily energy expenditure (TDEE) at your current weight. If intake equals or exceeds TDEE, the plateau is behavioral, not pharmacologic. Work with a dietitian or use structured meal planning to create a deficit.

Step 3: Assess total weight loss to date. If you've lost 15% or more of baseline body weight, you may be at a natural set point. Maintaining that loss on 2.4 mg is a success, not a failure. Discuss with your provider whether additional loss is medically necessary.

Step 4: If you've lost less than 10% of baseline weight after 6+ months at 2.4 mg, and Steps 1 and 2 are optimized, you're a candidate for switching to tirzepatide. Discuss with your provider.

Step 5: If tirzepatide is not an option (cost, supply, contraindication), consider adding metabolic adjuncts: metformin (off-label for weight loss, modest 2-3% additional loss), topiramate (off-label, 5-7% additional loss but significant side-effect burden), or naltrexone/bupropion (Contrave, FDA-approved, 5% additional loss). Do not increase semaglutide above 2.4 mg.

Steelmanning the case for higher doses

The strongest argument for dosing semaglutide above 2.4 mg is this: individual variation in drug metabolism and receptor sensitivity means some patients may require higher doses to achieve the same plasma concentration and receptor occupancy that others achieve at 2.4 mg.

Pharmacokinetic studies show that semaglutide clearance varies by up to 40% between individuals (Lau et al., Clinical Pharmacokinetics, 2015). A patient with high clearance might have lower steady-state concentrations at 2.4 mg than a patient with low clearance. If the dose-response relationship is driven by plasma concentration, not nominal dose, then some patients might benefit from 3.0 mg or higher.

This argument is pharmacologically plausible. The problem is that it's not testable without therapeutic drug monitoring (measuring semaglutide plasma levels), which is not commercially available or clinically validated. We don't know what the "therapeutic range" for semaglutide concentration is, so we can't identify which patients are underdosed at 2.4 mg.

A second argument: the STEP trials enrolled patients with baseline BMI of 30 or higher (or 27+ with comorbidities). Patients with BMI above 45 were underrepresented. It's possible that very high BMI patients require higher doses, and the 2.4 mg ceiling is appropriate for BMI 30-40 but insufficient for BMI 50+.

This is also plausible, but again, untested. The STEP 2 trial (Davies et al., Lancet, 2021) included patients with type 2 diabetes and mean baseline BMI of 34. Weight loss at 2.4 mg was 9.6%, lower than the 14.9% in STEP 1 (non-diabetic patients, mean BMI 38). But the difference could be due to diabetes status, not BMI.

The counterargument to both points: if higher doses were necessary for a subset of patients, Novo Nordisk would have tested them. The company has every financial incentive to identify and patent higher-dose regimens. The fact that they stopped at 2.4 mg suggests their internal data showed no benefit to going higher.

Until a randomized controlled trial tests semaglutide 3.0 mg, 4.0 mg, or 5.0 mg against 2.4 mg in patients who plateau, the case for higher dosing remains speculative.

Storage, missed doses, and dose-reduction protocols

Storage: Wegovy pens are stored in the refrigerator at 36 to 46°F (2 to 8°C) until first use. After first use, the pen can be kept at room temperature (up to 86°F) or refrigerated for up to 28 days. Do not freeze. Compounded semaglutide vials follow the same temperature rules but have a 28-day expiration after first puncture regardless of storage method.

Missed doses: If you miss a dose and it's been fewer than 5 days since the scheduled injection, inject as soon as you remember, then resume your normal weekly schedule. If it's been more than 5 days, skip the missed dose and inject the next dose on your regular day. Do not double-dose to "catch up."

Dose reduction: If you experience intolerable side effects at 2.4 mg (persistent nausea lasting more than 3 days, vomiting more than twice in 24 hours, severe abdominal pain), contact your provider. The standard protocol is to drop back to 1.7 mg for 4 weeks, then re-attempt 2.4 mg. If 2.4 mg is intolerable on the second attempt, 1.7 mg becomes your maintenance dose. Some patients maintain excellent weight loss at 1.7 mg and never need 2.4 mg.

Pen vs. vial administration: Wegovy pens are single-dose, pre-filled, and auto-inject. You twist the dose selector to 2.4 mg (it clicks into place), press the pen against your skin, and hold for 6 seconds. Compounded semaglutide comes in multi-dose vials and requires drawing the dose with a syringe. For 2.4 mg at the most common compounded concentration (5 mg/mL), you draw 48 units on a U-100 insulin syringe (0.48 mL). See our semaglutide unit conversion guide for full charts.

When to call your provider about dosing

Contact your provider within 24 hours if:

• You experience vomiting that prevents you from keeping down liquids for more than 12 hours.
• You have severe abdominal pain that doesn't resolve within 6 hours, particularly if it radiates to your back (possible pancreatitis).
• You notice a lump or swelling in your neck, difficulty swallowing, or persistent hoarseness (thyroid concerns, though medullary thyroid carcinoma risk is theoretical in humans).
• You have signs of an allergic reaction: hives, swelling of the face or throat, difficulty breathing.
• You accidentally injected more than your prescribed dose (e.g., 4.8 mg instead of 2.4 mg due to a syringe error).

Most side effects at 2.4 mg (mild nausea, occasional loose stools, injection-site redness) do not require immediate contact. Mention them at your next scheduled follow-up.

FAQ

What is the highest dose of Wegovy approved by the FDA? The highest FDA-approved Wegovy dose is 2.4 mg injected subcutaneously once weekly. This is the maintenance dose reached after a 16 to 20-week titration schedule. No higher dose has been studied or approved for weight management.

Can I take more than 2.4 mg of Wegovy if I'm not losing weight? Increasing Wegovy above 2.4 mg is off-label and not supported by clinical trial data. If you've plateaued at 2.4 mg, the evidence-based options are switching to tirzepatide, optimizing diet and exercise, or adding adjunct medications. Discuss with your provider before making any dose changes.

Is 2.4 mg of Wegovy the same as 2.0 mg of Ozempic? No. Wegovy 2.4 mg is the weight-loss maintenance dose. Ozempic 2.0 mg is the maximum diabetes dose. The drugs contain the same active ingredient (semaglutide) but are studied and approved for different indications at different doses.

How long does it take to reach the highest Wegovy dose? The standard titration schedule takes 16 weeks to reach 2.4 mg: 4 weeks each at 0.25 mg, 0.5 mg, 1.0 mg, and 1.7 mg, then escalation to 2.4 mg at week 17. Your provider may extend the schedule if you experience side effects.

What happens if I can't tolerate 2.4 mg? If 2.4 mg causes intolerable side effects, your provider will likely reduce you to 1.7 mg for 4 weeks, then re-attempt 2.4 mg. If 2.4 mg is still intolerable, 1.7 mg becomes your maintenance dose. Many patients achieve excellent weight loss at 1.7 mg.

Is compounded semaglutide dosed the same as Wegovy? Compounded semaglutide typically follows the same titration schedule and 2.4 mg maximum dose as Wegovy. However, some compounding pharmacies dose above 2.4 mg off-label. This practice is not evidence-based and carries increased risk of adverse events.

Can I switch from Wegovy 2.4 mg to tirzepatide? Yes. Switching from semaglutide to tirzepatide is common when patients plateau. The typical protocol is to taper semaglutide to 1.0 mg for one week, then start tirzepatide at 2.5 mg the following week. Your provider will guide the transition.

Does body weight affect the maximum Wegovy dose? No. The maximum dose is 2.4 mg for all patients regardless of body weight. The STEP trials did not use weight-based dosing. A 150-pound patient and a 300-pound patient both receive 2.4 mg at maintenance.

What if I accidentally inject 4.8 mg instead of 2.4 mg? Contact your provider immediately. Accidental overdose can cause severe nausea, vomiting, and dehydration. You may need monitoring or supportive care. Do not inject your next scheduled dose without provider guidance.

How much weight loss should I expect at 2.4 mg? In the STEP 1 trial, patients on 2.4 mg lost an average of 14.9% of baseline body weight at 68 weeks. Individual results vary widely. About 50% of patients lost 15% or more, while 30% lost less than 10%.

Can I stay on 2.4 mg indefinitely? The STEP 5 trial followed patients on 2.4 mg for 104 weeks (2 years) with good safety and sustained weight loss. Long-term data beyond 2 years is limited. Most patients remain on maintenance dosing as long as the medication is effective and tolerated.

Is there a higher-dose version of semaglutide for weight loss? No. Wegovy 2.4 mg is the highest-dose semaglutide product approved for weight management. Rybelsus (oral semaglutide) is approved up to 14 mg daily for diabetes, but this is not equivalent to injectable semaglutide and is not approved for weight loss.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
3. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
4. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
5. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
6. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
7. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
8. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023.
9. Patel R et al. Adverse events associated with off-label high-dose compounded semaglutide: a case series. Obesity. 2025.
10. Lau DCW et al. Clinical Pharmacokinetics and Pharmacodynamics of Semaglutide. Clinical Pharmacokinetics. 2015.
11. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
12. Wegovy (semaglutide) injection prescribing information. Novo Nordisk. 2021.
13. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes & Endocrinology. 2022.
14. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Rybelsus, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.